These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 354327)

  • 1. A six-month follow-up of refractory chronic psychotics treated with Haldol-AID.
    Wouters J
    Acta Psychiatr Belg; 1978; 78(2):399-406. PubMed ID: 354327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicentre study on the efficacy and safety of individualized dosage of haloperidol (Haldol) in refractory chronic psychotics.
    Nicodeme A; Vranckx-Haenen J; Wouters J
    Acta Psychiatr Belg; 1977; 77(4):516-29. PubMed ID: 337756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses.
    Roose K
    Acta Psychiatr Belg; 1982; 82(2):216-23. PubMed ID: 7180558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluation of the efficacy of haloperidol decanoate].
    Alvarez JV; Li Gambi M
    Acta Psiquiatr Psicol Am Lat; 1986 Sep; 32(3):233-6. PubMed ID: 2884807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
    Kane JM; Leucht S; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duration of neuroleptic treatment and relapse rate: a 5-year follow-up study with haloperidol decanoate.
    Youssef HA
    Clin Neuropharmacol; 1991; 14 Suppl 2():S16-21; discussion S22-3. PubMed ID: 1684308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Open clinical trial with haloperidol decanoate in patients with psychotic disorders].
    Ellerman LA
    Acta Psiquiatr Psicol Am Lat; 1987 Jun; 33(2):157-62. PubMed ID: 3321918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacological treatment of delusional depression].
    Amore M; Giordani L; Giorgetti G; Zazzeri N
    Minerva Psichiatr; 1996 Mar; 37(1):29-33. PubMed ID: 8804200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of age on the pharmacological management of ambulatory patients treated with depot neuroleptic medications for schizophrenia and related psychotic disorders.
    Mamo DC; Sweet RA; Chengappa KN; Reddy RR; Jeste DV
    Int J Geriatr Psychiatry; 2002 Nov; 17(11):1012-7. PubMed ID: 12404650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy.
    Wei FC; Jann MW; Lin HN; Piao-Chien C; Chang WH
    J Clin Psychiatry; 1996 Jul; 57(7):298-302. PubMed ID: 8666571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose treatment strategies.
    Van Putten T; Marder SR
    J Clin Psychiatry; 1986 May; 47 Suppl():12-6. PubMed ID: 2871010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of psychoses with a long-acting neuroleptic agent (fluphenazine decanoate). Clinico-psychopathological study of 53 patients].
    La Mura G; Specchio LM; Corfiati L; Porro V; Bertolino A
    Acta Neurol (Napoli); 1974; 29(4):446-59. PubMed ID: 4615572
    [No Abstract]   [Full Text] [Related]  

  • 16. [A long-acting neuroleptic. 3. Pilot study of penfluridol (R 16341)].
    Bobon J; Melon J; Mormont C; Dufrasne M; Pinchard A
    Acta Psychiatr Belg; 1970; 70(4):523-51. PubMed ID: 4923798
    [No Abstract]   [Full Text] [Related]  

  • 17. An open clinical trial with the long-acting neuroleptics flupenthixol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia.
    Kong DS; Yeo SH
    Pharmatherapeutica; 1989; 5(6):371-9. PubMed ID: 2687894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Movement disorders in patients treated with long-acting injectable antipsychotic drugs.
    Bransgrove LL; Kelly MW
    Am J Hosp Pharm; 1994 Apr; 51(7):895-9. PubMed ID: 7912473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Trial of interruption of antiparkinson drugs in long term treatments with neuroleptics].
    Caroli F; Littre-Poirier MF; Ginestet D; Deniker P
    Encephale; 1975; 1(1):69-74. PubMed ID: 805695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
    Chouinard G; Annable L; Campbell W
    J Clin Psychopharmacol; 1989 Aug; 9(4):247-53. PubMed ID: 2570086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.